Strattera is a brand name of atomoxetine, approved by the FDA in the following formulation(s):
STRATTERA (atomoxetine hydrochloride - capsule; oral)
Manufacturer: LILLY
Approval date: November 26, 2002
Strength(s): 10MG [AB], 18MG [AB], 25MG [AB], 40MG [AB], 60MG [RLD][AB]
Manufacturer: LILLY
Approval date: February 14, 2005
Strength(s): 100MG [AB], 80MG [AB]
Has a generic version of Strattera been approved?
A generic version of Strattera has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Strattera and have been approved by the FDA:
atomoxetine hydrochloride capsule; oral
Manufacturer: AUROBINDO PHARM
Approval date: September 13, 2010
Strength(s): 100MG [AB], 10MG [AB], 18MG [AB], 25MG [AB], 40MG [AB], 60MG [AB], 80MG [AB]
Manufacturer: MYLAN
Approval date: August 30, 2010
Strength(s): 100MG [AB], 10MG [AB], 18MG [AB], 25MG [AB], 40MG [AB], 60MG [AB], 80MG [AB]
Manufacturer: SANDOZ
Approval date: September 13, 2010
Strength(s): 100MG [AB], 10MG [AB], 18MG [AB], 25MG [AB], 40MG [AB], 60MG [AB], 80MG [AB]
Manufacturer: SUN PHARMA GLOBAL
Approval date: August 30, 2010
Strength(s): 100MG [AB], 10MG [AB], 18MG [AB], 25MG [AB], 40MG [AB], 60MG [AB], 80MG [AB]
Manufacturer: TEVA PHARMS
Approval date: October 1, 2010
Strength(s): 100MG [AB], 10MG [AB], 18MG [AB], 25MG [AB], 40MG [AB], 60MG [AB], 80MG [AB]
Manufacturer: ZYDUS PHARMS USA INC
Approval date: September 17, 2010
Strength(s): 100MG [AB], 18MG [AB], 25MG [AB], 40MG [AB], 60MG [AB], 80MG [AB]
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Strattera. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Treatment of attention-deficit/hyperactivity disorder
Patent 5,658,590
Issued: August 19, 1997
Inventor(s): Heiligenstein; John H. & Tollefson; Gary D.
Assignee(s): Eli Lilly and Company
Tomoxetine, a norepinephrine uptake inhibitor, is used to treat attention-deficit/hyperactivity disorder.Patent expiration dates:
- November 26, 2016✓
- May 26, 2017✓✓
- November 26, 2016
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- September 28, 2010 - USE IN SPECIFIC POPULATIONS - PATIENTS WITH CONCOMITANT ILLNESS SUBSECTION OF THE LABELING REGARDING USE OF STRATTERA IN PATIENTS WITH ADHD WHO HAVE COMORBID TIC DISORDER
- May 7, 2011 - MAINTENANCE TREATMENT OF ATTENTION-DEFICIT DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS
- July 23, 2011 - CLINICAL TRIAL INFO ON USE OF STRATTERA IN PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) AND COMORBID ANXIETY DISORDER WITHOUT CAUSING WORSENING OF ANXIETY
See also...
- Strattera Consumer Information (Drugs.com)
- Strattera Consumer Information (Wolters Kluwer)
- Strattera Consumer Information (Cerner Multum)
- Strattera Advanced Consumer Information (Micromedex)
- Strattera AHFS DI Monographs (ASHP)
- Atomoxetine Consumer Information (Wolters Kluwer)
- Atomoxetine Consumer Information (Cerner Multum)
- Atomoxetine Advanced Consumer Information (Micromedex)
- Atomoxetine Hydrochloride AHFS DI Monographs (ASHP)
No comments:
Post a Comment